PHVS (Pharvaris NV) GF Score: 22/100 (As of Jul. 11, 2026) — Near Median


PHVS Pharvaris NV PHVS
22 GF Score
Price $35.02
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV GF Score?

Pharvaris NV PHVS -2.39% 22 GF Score is 22 as of Jul. 11, 2026, which is at its 10-year median of 22.00. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Pharvaris NV has the GF Score of 22, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Pharvaris NV might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pharvaris NV  (NAS:PHVS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Pharvaris NV GF Score Related Terms

PHVS vs BHVN, NRIX, VCEL: GF Score Comparison

For the Biotechnology subindustry, Pharvaris NV's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's GF Score distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's GF Score falls into.


PHVS
22GF Score
Pharvaris NV PHVS
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 22 mean?
Pharvaris NV (PHVS) has a GF Score of 22 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pharvaris NV and its competitors. This is near median its historical median of 22.00. Over the past decade, Pharvaris NV's GF Score has ranged from 15.00 to 44.00.
Is Pharvaris NV's GF Score too high?
Pharvaris NV's current GF Score of 22 is near median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 15.00 to a high of 44.00. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's GF Score compare to BHVN and NRIX?
Pharvaris NV's GF Score of 22 can be compared against companies in the Biotechnology industry. Historically, Pharvaris NV's own GF Score has ranged from 15.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Pharvaris NV and its competitors. Pharvaris NV's current GF Score is 22, which is near median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current GF Score of 22. The current GF Score is 22, which is near median its 10-year median of 22.00. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current GF Score is 22 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.02
Price